KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or “The Company”), today announced its financial results for the fourth quarter and year ended December 31, 2015.
Provectus is holding its previously announced conference call at 4 p.m. (EDT) today to discuss the Company's 2015 financial results and answer questions from investors.
Provectus is holding its previously announced conference call at 4 p.m. (EDT) today to discuss the Company's 2015 financial results and answer questions from investors.
